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Study Objective: To evaluate the effects of noninvasive 
ventilation (NIV) on sleep in patients with amyotrophic 
lateral sclerosis (ALS) after meticulous titration with 
polysomnography (PSG).
Methods: In this prospective observational study, 24 ALS 
patients were admitted to the sleep laboratory during 4 
nights for in-hospital NIV titration with PSG and nocturnal 
capnography. Questionnaires were used to assess subjective 
sleep quality and quality of life (QoL). Patients were readmitted 
after one month.
Results: In the total group, slow wave sleep and REM sleep 
increased and the arousal-awakening index improved. The 
group without bulbar involvement (non-bulbar) showed the 
same improvements, together with an increase in sleep 
effi ciency. Nocturnal oxygen and carbon dioxide levels 
improved in the total and non-bulbar group. Except for oxygen 
saturation during REM sleep, no improvement in respiratory 
function or sleep structure was found in bulbar patients. 
However, these patients showed less room for improvement. 
Patient-reported outcomes showed improvement in sleep 
quality and QoL for the total and non-bulbar group, while 
bulbar patients only reported improvements in very few 
subscores.
Conclusions: This study shows an improvement of sleep 
architecture, carbon dioxide, and nocturnal oxygen saturation 
at the end of NIV titration and after one month of NIV in ALS 
patients. More studies are needed to identify the appropriate 
time to start NIV in bulbar patients. Our results suggest that 
accurate titration of NIV by PSG improves sleep quality.
Commentary: A commentary on this article appears in this 
issue on page 511.
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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder primarily affecting the motor system and is char-
acterized by progressive decrease in muscle strength. In ad-
dition to weakness of peripheral muscles, respiratory muscle 
weakness develops during the course of the disease, leading to 
reduced alveolar ventilation and respiratory failure, which is 
the main cause of death in ALS.1,2
A randomized controlled trial showed improvement in sur-
vival and quality of life (QoL) in ALS patients treated with 
noninvasive ventilation (NIV).3 Although survival in the sub-
group of patients with severe bulbar impairment did not im-
prove, small improvements in QoL were observed.
Sleep is often disturbed in ALS patients.4–7 In the presence 
of diaphragmatic dysfunction, REM sleep decreases.8 Further-
more, sleep disturbances and nocturnal desaturations have 
been observed in ALS patients with normal respiratory func-
tion and preserved diaphragmatic innervation.9
Although NIV is predominantly used at night, few studies 
have examined the effect on sleep in ALS. Nevertheless, NIV 
could have a negative impact on sleep: wearing a mask and 
having air blown into the nose and/or mouth do not seem to 
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create the perfect circumstances for good sleep quality. In the 
presence of weakness of facial or bulbar muscles, application of 
the mask could create diffi culties, resulting in non-intentional 
leaks. Furthermore, diffi culties with swallowing and manag-
ing secretions could interfere with NIV during sleep.10 Con-
versely, improvement of oxygenation and carbon dioxide levels 
would have benefi cial effects on sleep. Most studies dealing 
with sleep in ALS are based on patient-reported outcomes and 
reported improved sleep after NIV initiation.3,11–14 Only two 
BRIEF SUMMARY
Current Knowledge/Study Rationale: Previous research has shown 
an improvement in survival and quality of life after initiation of NIV in 
ALS. Until now, no improvement in objective sleep parameters has been 
found; however, NIV was titrated during daytime. More detailed titration 
with polysomnography could perhaps improve quality of sleep.
Study Impact: This study shows that NIV titration with polysomnog-
raphy improves objective sleep outcomes in ALS patients. Hence, me-
ticulous titration of NIV has an important clinical impact in this patient 
group. Further research is necessary to create evidence to fi nd the cor-
rect time to start NIV in bulbar ALS patients.
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studies used polysomnography (PSG) to evaluate sleep during 
NIV and did not demonstrate improvement in sleep. Katzberg 
et al. showed an improved oxygenation but no improvement in 
sleep efficiency (SE), sleep arousals and sleep architecture dur-
ing NIV.15 Atkeson et al. showed a high frequency of patient-
ventilator asynchronies (PVA).16 Therefore, additional studies 
evaluating the effect of NIV on sleep are needed.17
The aim of this prospective study was to evaluate the influ-
ence of NIV on sleep in ALS by PSG with capnography before 
and after one month of NIV. Correlations were searched be-
tween therapeutic compliance with carbon dioxide measure-
ment, improvement in patient-reported outcomes (total scores), 
and improvement in objective sleep parameters. Although a 
previous study shows no improvement in sleep structure,15 we 
hypothesized that improvement in sleep structure could be 
found with a more meticulous NIV titration.
METHODS
Patients
At University Hospitals Leuven, ALS patients are routinely 
followed at the Neuromuscular Reference Centre (NMRC) in 
collaboration with pulmonologists (BB, DT). Patients with 
decreased inspiratory muscle strength (maximal inspiratory 
mouth pressure [MIP] < 60 cm H2O), restrictive pulmonary 
function (vital capacity [VC] < 80% of the predicted value) 
and at least one of the following criteria were offered NIV: 
symptoms of nocturnal alveolar hypoventilation, increased 
daytime arterial carbon dioxide ([PaCO2] > 45 mm Hg) or 
an increase ≥ 10 mm Hg in transcutaneous carbon dioxide 
(PtcCO2) during sleep compared to their awake supine value 
(≥ 40 mm Hg). These inclusion criteria ensured that all patients 
in this study fulfilled the NIV criteria according to the guide-
lines of the American Academy of Neurology and the guide-
lines of the European Federation of Neurological Societies in 
ALS patients.18,19
Methods
Patients were admitted to the sleep lab for 5 days and 4 
nights. Diagnostic PSG was performed on the first night. The 
next morning, NIV was started (Trilogy 100, Philips Respiron-
ics, Murrysville, PA, USA) with a nasal mask. Patients were 
accustomed to NIV in spontaneous (S) mode with an inspi-
ratory positive airway pressure (IPAP) of 8 cm H2O and an 
expiratory positive airway pressure (EPAP) of 4 cm H2O. In 
the afternoon, IPAP was titrated in S mode during a nap to 
reach a tidal volume of 6 mL/min/kg ideal body weight. In the 
morning of days 3, 4, and 5, PSG was analyzed and NIV set-
tings were adjusted according to nocturnal PtcCO2, oxygen sat-
uration (SpO2%), and occurrence of respiratory events. Each 
afternoon the patient napped for 1 hour to get accustomed to 
the new settings. In the presence of mouth leaks, a chin strap 
or oronasal mask was applied. After 1 month of NIV, patients 
were readmitted for PSG.
PSG (Medatec, Brainnet II, Brussels, Belgium) was used to 
record sleep and respiratory parameters. Sleep was scored and 
calculated after visual inspection of the tracings, according to 
the guidelines of the American Academy of Sleep Medicine 
(AASM) by 2 physicians with large experience in PSG analy-
sis.20 During diagnostic PSG, airflow was detected by a therm-
istor (Braebon, NY, USA) and nasal pressure cannula system 
(Teleflex Medical, NC, USA). A pneumotachograph (Hamilton 
Medical, Bonaduz, Switzerland) was used to record flow dur-
ing NIV titration. Apnea and hypopnea were scored accord-
ing to the AASM 2012 guidelines.21 PtcCO2 was continuously 
monitored by a Tosca 500 monitor (Radiometer Ltd., Bronshoj, 
Denmark). The PtcCO2 and pneumotachograph data were in-
corporated in the PSG software and continuously followed.
Before and after 1 month of NIV, patients performed a VC 
measurement in sitting and (if possible) supine position ac-
cording to the guidelines of the European Respiratory Soci-
ety,22 with prediction equations as proposed by Quanjer.23 
Daytime arterial blood gas (ABG) analysis was carried out 
in sitting position without ventilatory support. Measurements 
of MIP and sniff nasal inspiratory pressure (SNIP) were per-
formed (MicroRPM, Micro Medical, Brooklyn, NY, USA).24,25 
Patients completed questionnaires concerning sleep, QoL, and 
functionality. The Pittsburgh Sleep Quality Index (PSQI) and 
the Epworth Sleepiness Scale (ESS) were used to measure 
sleep quality and daytime sleepiness, respectively.26,27 Apart 
from the short-form 36 health questionnaire (SF-36), a generic 
measurement searching for health-related QoL,28 we employed 
the McGill Quality of Life questionnaire (MQoL) measuring 
QoL specifically in patients with a life-threatening disease.29 
Functionality was measured by the revised Amyotrophic Lat-
eral Sclerosis Functional Rating Scale (ALSFRS-R).30 Bulbar 
function was based on the first 3 questions of the ALSFRS-R, 
and patients were classified as bulbar when this score was ≤ 9.31
This study was registered at clinicaltrials.gov (NCT01889043) 
and approved by the local ethical committee (ML7674). Writ-
ten informed consent was obtained from all participants.
Statistical Analysis
Statistical analyses were performed with SAS 9.0 (SAS Insti-
tute Inc., Cary, NC, USA). Data are reported as mean ± standard 
deviation or as median and interquartile range. Comparisons 
between pre and post measurements were performed by paired 
t-test or Wilcoxon signed-rank test, depending whether data 
were normally distributed or not. Between-group compari-
sons were performed by unpaired t-test or Mann-Whitney test. 
Spearman rho and Pearson were used to test correlations. Re-
sults were considered significant when p < 0.05. Figures were 
made by GraphPad Prism 5.01 (GraphPad Software Inc., La 
Jolla, CA, USA).
RESULTS
From January 2012 to April 2013, 63 patients were referred 
to our unit by the NMRC. Twenty-four patients (60 ± 10 years, 
21 males) were started on NIV (Figure 1). Demographic data 
and baseline measurements of inspiratory muscle strength, 
VC, and ABG are shown in Table 1. Measurement of supine 
VC could not be performed in 7 patients because of severe or-
thopnea. Three patients refused ABG analysis, and 2 patients 
had problems performing MIP/SNIP measurement. The most 
prevalent symptoms of alveolar hypoventilation were orthop-
nea (20 patients), increased daytime sleepiness (17 patients), 
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frequent awakenings (15 patients), and exertional dyspnea (12 
patients). In our group, 10 patients showed important bulbar 
involvement and were classified as “bulbar”; 14 patients were 
classified as “non-bulbar.”
Seventeen patients were discharged from the hospital on 
spontaneous/timed (S/T) mode and 7 patients on S mode, due 
to intolerance of S/T mode (5 of these patients had bulbar 
involvement with residual saliva and swallowing problems 
which aggravated with the S/T mode and thereby influencing 
their subjective and objective sleep quality). Nineteen patients 
were ventilated by nasal mask and 5 patients by oronasal mask. 
IPAP was set at 14 ± 2 cm H2O and EPAP was set at 4 ± 1 cm 
H2O. Patients on S/T mode had a back-up frequency of 16 ± 2/
min. One non-bulbar male patient died of pneumonia before 
follow-up, and one bulbar male patient could not be tested with 
NIV after one month because of intolerance (1.8 h/day use, 
only during daytime). These 2 patients were excluded from 
further analysis.
After one month (38 ± 9 days), ALSFRS-R was significantly 
decreased (p < 0.01 for all patients; p < 0.05 for non-bulbar 
patients or bulbar patients). Daytime PaCO2 decreased signifi-
cantly in the total group (46 ± 6 vs. 43 ± 5 mm Hg, p < 0.05) 
and non-bulbar patients (48 ± 6 vs. 43 ± 5 mm Hg, p < 0.05).
Sleep Architecture
At baseline, PSG revealed poor sleep quality (Table 2). A 
low SE, with low percentages of slow wave sleep (N3) and 
REM sleep, and an increased arousal-awakening index (AAI) 
were present.32 Sleep quality of bulbar patients was better than 
sleep quality of non-bulbar patients, with less stage 1 sleep 
(N1), more REM sleep, and a lower AAI. Except for one pa-
tient who had no N3, all sleep stages were present in bulbar 
patients, while N3 and REM sleep were absent in 8 and 5 non-
bulbar patients, respectively.
After one month, several changes in sleep architecture were 
present. AAI and percentage of N1 sleep were significantly re-
duced and percentages of N3 and REM sleep were significantly 
increased (while total sleep time was not significantly higher) 
in all patients. The same observations were made in the group 
of non-bulbar patients, with even a significant increase in SE. 
In the non-bulbar group all sleep stages were now present in all 
patients but one. In the bulbar patients, no improvement in SE, 
sleep stages, or AAI was found (Table 2).
Analyzing PSG of the night with the final settings during 
the start-up procedure already found improvements in sleep 
structure compared to diagnostic PSG. The total group showed 
improvement in AAI (17 [12–21] per hour of sleep; p < 0.01) 
and the amount of N1 (4 [2–9] %; p < 0.01), N3 (19 [8–30] %; 
p < 0.01) and REM (21 [14–26] %; p < 0.05) sleep, while the 
non-bulbar group showed improvement in SE (81 [67–84] %; 
p < 0.01), AAI (18 [13–22] per hour of sleep; p < 0.01), and N1 
(3 [2–9] %; p < 0.01), N3 (19 [4–30] %; p < 0.05), and REM 
(25 [20–29] %; p < 0.01) sleep. Bulbar patients showed no im-
provement at discharge.
Sleep Respiratory Parameters
At diagnostic PSG, patients showed few obstructive events 
(0.0 [0.0–0.3] obstructive apneas per hour of sleep; 0.1 [0.0–
6.3] obstructive hypopneas per hour of sleep). Table 3 shows 
improvements in SpO2% and PtcCO2. In the total group the 
time spent with SpO2% < 90% improved during the total night 
as well as in REM and N1 and stage 2 (N2) sleep. Time spent 
with PtcCO2 > 55 mm Hg improved during the total night mea-
surement, N1, N2, and N3 sleep. Non-bulbar patients showed 
significant changes in the same parameters as the total group. 
Additionally, a trend to improvement was found for time spent 
with SpO2% < 90% in N3 (p = 0.0579). Bulbar patients only 
Figure 1—Flow chart of patient inclusion.
NMRC, neuromuscular reference centre; NIV, noninvasive ventilation; 
LUCS, Leuven University Centre For Sleep/Wake Disorders.
Table 1—Demographic data and baseline measurements 
of arterial blood gases, vital capacity, and inspiratory 
muscle strength.
 All
(n = 24)
Non-bulbar 
(n = 14)
Bulbar 
(n = 10)
Sex (male/female) 21/3 13/1 8/2
Age (years) 60 ± 10 61 ± 8 58 ± 13
Time from ALS symptom 
onset (months)
26 ± 13 27 ± 14 25 ± 12
Daytime PaCO2 (mm Hg) 46 ± 6 48 ± 6 42 ± 3*
Daytime PaO2 (mm Hg) 77 ± 12 72 ± 12 86 ± 7*
VCseat (%pred) 56 ± 14 60 ± 16 51 ± 10
VCsup (%pred) 41 ± 9 43 ± 11 38 ± 8
MIP (cm H2O) −35 ± 12 −38 ± 11 −30 ± 13
SNIP (cm H2O) −25 ± 21 −22 ± 26 −30 ± 11
Data are given as mean ± standard deviation. *p < 0.05 bulbar vs. non-
bulbar. PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, 
partial pressure of oxygen in arterial blood; VCseat, seated vital capacity; 
VCsup, supine vital capacity; MIP, maximal inspiratory pressure; SNIP, 
sniff nasal inspiratory pressure. 
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improved in time spent with SpO2% < 90% in REM sleep. In the 
bulbar group, no changes were found in PtcCO2 measurement.
Analyzing the data of SpO2% and PtcCO2 of the night with 
the final settings during titration showed improvements in 
comparison with the diagnostic PSG. The total group im-
proved in the time spent with SpO2% < 90% during the total 
night (4 [0–49] %; p < 0.01), N1+N2 (3 [0–48] %; p < 0.01), and 
REM (1 [0–50] %; p < 0.01) sleep, and also in time spent with 
PtcCO2 > 55 mm Hg during the total night (0 [0–21] %; p < 0.01) 
and N1+N2 sleep (20 [0–16] %; p < 0.05). The non-bulbar pa-
tients improved in time spent with SpO2% < 90% during the 
total night (5 [1–61] %; p < 0.05), N1+N2 (4 [0–72] %; p < 0.05) 
and REM (2 [0–60] %; p < 0.05) sleep and time spent with 
PtcCO2 > 55 mm Hg during the total night (0 [0–17] %; p < 0.01) 
and N1+N2 (0 [0–14] %; p < 0.05) sleep, while bulbar patients 
only improved in the time spent with SpO2% < 90% during 
REM sleep (1 [0–18] %; p < 0.05).
Questionnaires
Table 4 shows the data of the ESS, PSQI, and MQoL be-
fore and after one month of NIV. Non-bulbar patients showed 
improvements in daytime sleepiness (8.0 [3.5–11.5] vs 4.0 
[3.0–7.0]; p < 0.05), the PSQI total score (8.0 [6.5–14.5] vs 
5.0 [2.5–7.5]; p < 0.01), MQoL total score (5.0 [4.2–6.0] vs 
6.8 [5.4–7.9]; p < 0.01), and several subscales. In contrast, 
bulbar patients only reported an improved PSQI total score 
(9.0 [6.5–12.5] vs 5.0 [4.0–9.0]; p < 0.01) and sleep duration 
(1.0 [0.0–2.0] vs 0.0 [0.0–0.5]; p < 0.01). Improvements were 
found in the SF-36 emotional health subscale for the total (50 
[28–77] vs 62 [56–81]; p < 0.0001), non-bulbar (50 [29–84] 
vs 68 [54–90]; p < 0.01), and bulbar group (50 [25–67] vs 
60 [56–77]; p < 0.01). Vitality changed only for the total (35 
[10–50] vs 50 [29–60]; p < 0.05) and non-bulbar groups (25 
[10–49] vs 48 [26–60]; p < 0.01).
Compliance
Therapeutic compliance was significantly correlated with 
initial daytime PaCO2 (Figure 2A). Furthermore, NIV use 
was correlated with baseline nocturnal PtcCO2 and changes 
in PtcCO2 measurements over 1 month (Table 5). Figure 2B 
shows a statistical significant relationship between compliance 
and change in MQoL total score in the total group and non-
bulbar group. No correlation was found between therapeutic 
compliance and change in any objective sleep parameter.
DISCUSSION
This is the first study demonstrating improvements in sleep 
architecture and respiratory parameters in ALS patients dur-
ing treatment with nocturnal NIV, measured by PSG. The total 
Table 2—Sleep structure in all, non-bulbar and bulbar patients before and after one month of NIV use.
All (n = 22) Non–bulbar (n = 13) Bulbar (n = 9)
Pre Post Pre Post Pre Post
TST (min) 317 (216–442) 351 (261–455) 311 (107–428) 364 (273–457)* 350 (287–454) 337 (241–436)
SE (%) 59 (40–72) 68 (50–80) 62 (19–81) 72 (52–85)* 59 (49–65) 68 (44–74)
N1 (%) 11 (6–32) 8 (4–14)* 23 (8–56) 5 (4–11)** 7 (5–13) # 9 (6–17)
N2 (%) 63 (37–75) 54 (46–63) 63 (36–77) 55 (49–63) 65 (42–75) 53 (33–64)
N3 (%) 1 (0–10) 15 (8–19)* 0 (0–6) 16 (13–19)* 7 (1–18) 12 (1–21)
REM (%) 9 (1–16) 18 (9–23)* 6 (0–12) 22 (10–23)** 17 (7–25) ## 16 (9–23)
AAI (n/h) 37 (16–55) 17 (11–21)** 42 (36–82) 17 (12–26)** 16 (13–37) # 18 (11–20)
*p < 0.05 pre vs. post. **p < 0.01 pre vs. post. #p < 0.05 bulbar vs. non-bulbar. ##p < 0.01 bulbar vs. non-bulbar. TST, total sleep time; SE, sleep efficiency; 
N1, stage 1 sleep; N2, stage 2 sleep; N3, slow wave sleep; REM, rapid eye movement sleep; AAI, arousal-awakening index; pre, before NIV; post, after 1 
month of NIV. 
Table 3—Measurements of oxygen saturation and transcutaneous carbon dioxide measurements at baseline and after one 
month of NIV treatment.
All (n = 22) Non-bulbar (n = 13) Bulbar (n = 9)
Pre Post Pre Post Pre Post
SpO2 total night < 90 (%) 11.1 (1.1–59.9) 0.8 (0–6.2) ** 29.7 (3.7–98.0) 1.1 (0.2–100.0) ** 6.4 (0.2–33.5) 0.0 (0.0–9.6)
SpO2 REM < 90 (%) 35.3 (2.1–100.0) 0.5 (0.0–3.0) ** 37.1 (12.6–100.0) 0.9 (0.0–7.1) * 33.4 (0.2–82.5) 0.1 (0.0–2.5) *
SpO2 N3 < 90 (%) 8.3 (0.0–72.0) 0.0 (0.0–0.1) 57.3 (4.3–100.0) 0.0 (0.0–0.1) 1.8 (0.0–44.1) 0.0 (0.0–16.8)
SpO2 N1+N2 < 90 (%) 10.4 (1.4–97.9) 0.0 (0.0–6.2) ** 48.0 (2.3–99.1) 0.2 (0.0–7.7) ** 7.7 (0.5–58.9) 0.0 (0.0–7.0)
PtcCO2 total night > 55 (%) 42.5 (0.1–95.4) 0.0 (0.0–5.7) ** 78.7 (5.2–95.9) 0.0 (0.0–6.2) * 2.6 (0.0–76.1) 0.0 (0.0–5.2)
PtcCO2 REM > 55 (%) 0.8 (0.0–100.0) 0.0 (0.0–14.6) 52.8 (0.0–100.0) 0.0 (0.0–8.3) 0.0 (0.0–100.0) 0.0 (0.0–46.7)
PtcCO2 N3 > 55 (%) 55.8 (0.0–100.0) 0.0 (0.0–0.0) * 100.0 (75.0–100.0) 0.0 (0.0–0.0) * 0.0 (0.0–77.9) # 0.0 (0.0–0.0)
PtcCO2 N1+N2 > 55 (%) 50.3 (0.0–98.1) 0.0 (0.0–2.3) ** 89.4 (0.0–98.9) 0.0 (0.0–1.1) * 2.2 (0.0–85.1) 0.0 (0.0–3.4)
Data are given as median (25th–75th percentile). *p < 0.05 pre vs. post. **p < 0.01 pre vs. post. #p < 0.05 bulbar vs. non-bulbar. SpO2, oxygen saturation; 
PtcCO2, transcutaneous carbon dioxide; REM, rapid eye movement sleep; N3, slow wave sleep; N1+N2, stage 1 and 2 sleep; Pre, before NIV; post, after 
one month of NIV. 
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group and subgroup of non-bulbar patients showed improve-
ments in SE, amount of N3 and REM sleep, AAI, and oxy-
genation and carbon dioxide levels present at the end of the 
titration procedure; these improvements remained after one 
month of NIV use. In addition, patients also reported better 
sleep with less somnolence during daytime and improvement 
in QoL. In bulbar patients, improvements were limited, with 
no change in sleep architecture, small improvement in noctur-
nal SpO2%, and few subjective improvements.
In our study, NIV improved (apart from gas exchange) PSG-
recorded and patient-reported sleep and QoL. Few studies 
showed improvement in sleep by patient-reported outcomes in 
ALS. Lyall et al. did not make a distinction between bulbar 
and non-bulbar patients, but VC in their patients was simi-
lar to our group. Without specifying time of follow-up, they 
found a significant improvement in ESS score.12 Butz et al. 
showed a long-term improvement of sleep quality by using the 
PSQI, also without distinction between bulbar and non-bulbar 
Table 4—Measurements of Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality index (PSQI), and McGill quality of life 
questionnaire (McGill) at baseline and after one month.
All (n = 22) Non-bulbar (n = 13) Bulbar (n = 9)
Pre Post Pre Post Pre Post
ESS 8.0 (3.8–10.0) 4.5 (3.0–7.3) * 8.0 (3.5–11.5) 4.0 (3.0–7.0) * 8.0 (2.5–9.5) 6.0 (2.5–9.0)
PSQItot 8.5 (6.8–13.3) 5.0 (3.0–8.3) ** 8.0 (6.5–14.5) 5.0 (2.5–7.5) ** 9.0 (6.5–12.5) 5.0 (4.0–9.0) **
PSQIqual 1.5 (1.0–2.0) 1.0 (0.0–1.0) ** 2.0 (1–2.5) 0.0 (0.0–1.0)** 1.0 (0.5–2.0) 1.0 (1.0–1.0)
PSQIlat 1.0 (0.0–2.3) 0.5 (0.0–1.3) 0.0 (0.0–2.0) 0.0 (0.0–1.0) 2.0 (0.5–3.0) 1.0 (0.5–2.0) #
PSQIdur 1.0 (0.0–2.0) 0.0 (0.0–0.0) ** 1.0 (0.0–2.5) 0.0 (0.0–0.0) * 1.0 (0.0–2.0) 0.0 (0.0–0.5) **
PSQIeff 2.0 (0.0–3.0) 0.0 (0.0–1.0) ** 2.0 (0.0–3.0) 0.0 (0.0–0.5) * 2.0 (0.0–3.0) 0.0 (0.0–1.0)
PSQIdist 1.0 (1.0–2.0) 1.0 (1.0–1.0) ** 1.0 (1.0–2.0) 1.0 (1.0–1.0) ** 1.0 (1.0–2.0) 1.0 (1.0–1.5)
PSQImed 0.0 (0.0–3.0) 0.0 (0.0–2.3) 0.0 (0.0–3.0) 0.0 (0.0–3.0) 0.0 (0.0–2.5) 0.0 (0.0–0.5)
PSQIdysf 2.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–1.5) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
MQoLSIS 5.0 (3.0–7.0) 7.0 (4.8–7.0) 5.0 (2.5–7.0) 7.0 (4.5–8.0) * 5.0 (3.0–7.5) 5.0 (4.5–7.0)
MQoLtot 5.1 (4.1–6.3) 6.3 (5.0–7.5) ** 5.0 (4.2–6.0) 6.8 (5.4–7.9) ** 5.9 (3.8–6.9) 6.1 (4.9–6.8)
MQoLphyssym 3.3 (1.8–5.4) 5.0 (3.7–7.5) * 2.7 (1.7–4.5) 5.3 (4.2–7.2) * 4.7 (2.2–7.0) 4.6 (2.5–8.7)
MQoLphyswb 4.0 (3.0–5.3) 5.0 (3.8–7.0) * 3.0 (3.0–4.5) 6.0 (4.5–7.0) * 5.0 (2.0–6.5) 4.0 (3.0–6.0)
MQoLpsysym 4.9 (2.5–7.0) 7.0 (5.3–8.5) * 3.8 (2.3–6.8) 7.3 (5.1–8.5) * 6.5 (3.6–7.7) 7.0 (5.1–8.3)
MQoLexiwb 5.8 (4.2–6.8) 6.3 (4.6–7.6) 5.7 (3.7–6.9) 7.0 (3.5–8.3) 5.8 (4.2–6.8) 5.6 (5.2–6.5)
MQoLsupp 8.3 (6.8–10.0) 8.0 (6.9–9.5) 9.0 (7.3–10.0) 9.0 (7.8–9.8) 7.0 (5.0–9.3)# 7.0 (6.3–8.0)
Data are given as median (25th–75th percentile). *p < 0.05 pre vs. post. **p < 0.01 pre vs. post. #p < 0.05 bulbar vs. non-bulbar. ESS, Epworth Sleepiness 
Scale; PSQItot, Pittsburgh Sleep Quality index total score; PSQIqual, sleep quality; PSQIlat, sleep latency; PSQIdur, sleep duration; PSQIeff, sleep efficiency; 
PSQIdist, sleep disturbances; PSQImed, sleep medication; PSQIdysf, sleep dysfunction; MQoLSIS, McGill Quality of Life questionnaire single item scale; 
MQoLtot, total score; MQoLphyssym, physical symptoms; MQoLphyswb, physical well-being; MQoLpsysym; psychological symptoms; MQoLexiwb, existential well-
being; MQoLsupp, support; Pre, before NIV; Post, after one month of NIV. 
Figure 2—Correlation between therapeutic compliance and daytime arterial carbon dioxide before NIV and change in quality 
of life.
(A) Correlation between daytime arterial carbon dioxide (n = 19) before NIV initiation and use hours: r = 0.54, p < 0.05. (B) Correlation between change 
in the total score of the McGill questionnaire (ΔMQoLtot) and use hours in the total group (r = 0.56, p < 0.01) and non-bulbar group (gray dots) (r = 0.63, 
p < 0.05). PaCO2, partial pressure of carbon dioxide in arterial blood; ΔMQoLtot, change in the total score of the McGill Quality of Life questionnaire.
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involvement.11 In the randomized controlled trial, Bourke et al. 
used the symptom subscale of the Sleep Apnea Quality of Life 
Index (SAQLI) and found an improvement of symptoms in the 
total group and in patients with good bulbar function.3 Patients 
with poor bulbar function had no improvement, except for the 
time-weighted mean of the SAQLI symptom score. Although 
our bulbar patients used NIV 6.4 h/day, compared to 3.8 h/
day in the study of Bourke et al., we also found no significant 
changes in our bulbar group (PSG or patient-reported), except 
for the total PSQI score and its subscale of sleep duration.
To our knowledge, only one study evaluated PSG recorded 
sleep architecture in ALS patients on NIV.15 Our results are in 
contrast with this study as it showed no change in SE, sleep 
arousals, or sleep architecture. Several factors could explain 
these differences. In Katzberg’s study, NIV was titrated dur-
ing daytime according to the patient’s comfort. In our study, 
NIV was titrated by PSG guidance; hence, sleep structure was 
taken into account during titration. Furthermore, the NIV de-
vice itself could influence sleep due to possible differences in 
triggering. In our study, the Trilogy 100 was used with the Au-
toTrak setting. Katzberg et al. did not mention their trigger mo-
dality, but fixed trigger sensitivity could influence the number 
of PVAs and AAI, as trigger sensitivity could possibly differ 
between sleep stages.33–36 Another difference is the use of aver-
age volume-assured pressure support (AVAPS) in Katzberg’s 
study. Until now, no randomized controlled trial with AVAPS 
has been performed in ALS. Impact of self-changing pressures 
on leaks, PVA, and sleep is therefore unknown. Although in a 
heterogenic group of neuromuscular patients, volume-targeted 
ventilation has shown to cause more PVA than pressure sup-
port ventilation.37 Katzberg et al. already suggested that an ad-
ditional night of PSG to titrate NIV would have been helpful to 
optimize treatment in their cohort.15 In stable neuromuscular 
patients, with at least 3 months of NIV use, 66% still showed 
a PSQI score ≥ 5 (mean score 6.98 ± 3.2).38 In that study, NIV 
was established following evaluation of diurnal comfort, respi-
ratory function, and gas exchange, and of nocturnal in-hospi-
tal cardiorespiratory polygraphic monitoring, but without any 
sleep study. As most patients still showed poor sleep quality, 
the authors stated that great care should be paid to an effective 
and optimal NIV setting. Indeed, as the median (interquartile 
range) PSQI score in our study before NIV was 8.5 (6.8–13.3) 
and decreased to 5.0 (3.0–8.3), with even a significant improve-
ment in the bulbar patients, it seems that PSG could be of major 
importance to improve sleep quality in patients starting with 
NIV.
The most striking result of this study is that NIV improved 
PSG-recorded and patient-reported sleep, QoL, nocturnal 
SpO2%, and carbon dioxide in the total and non-bulbar group 
of patients, but that almost no improvements were found in the 
group of bulbar patients. An explanation could be compiled 
from the data before NIV initiation; PSG recorded sleep qual-
ity, SpO2%, and carbon dioxide measurements were better in 
the bulbar group and therefore, there is less room for improve-
ment. The question then arises whether NIV is started too 
soon in bulbar patients, as also PaCO2 was lower and SNIP was 
slightly higher. These patients frequently complain of orthop-
nea but this sensation is probably partly induced by breathing 
difficulties due to accumulation of secretions and/or excessive 
saliva. On the other hand, postponing NIV in bulbar patients 
could impede NIV titration and adjustment to a mask second-
ary to advanced bulbar symptoms. This point of discussion 
becomes even more complicated if we consider our bulbar pa-
tients individually. Indeed, sleep and QoL did not improve in 
patients with a very low score on the bulbar questions of the 
ALSFRS-R, but patients with a score of 8 and 9 had variable 
results. It could be suggested that NIV should be initiated in 
patients with bulbar involvement when decreased sleep quality 
is reported by the patient or PSG, but certainly more research 
on when to start NIV in bulbar ALS patients is necessary.
Correlation was found between therapeutic compliance 
and nocturnal time spent above 55 mm Hg PtcCO2 at baseline. 
This is in agreement with Kim et al. who showed that duration 
of nocturnal hypercapnia, measured by end-tidal capnogra-
phy, was predictive for good compliance.39 This finding could 
promote early measurement of nocturnal PtcCO2, even in nor-
mocapnic patients during daytime, and together with the cor-
relation between compliance and change of nocturnal PtcCO2, 
encourage good compliance. Even a simple daytime PaCO2 
measurement was correlated with future compliance. Appar-
ently, patients with high PaCO2 need less encouragement on 
their compliance, but patients with mild hypercapnia should 
be well observed to increase compliance. Our results show a 
positive correlation between change in QoL and therapeutic 
compliance in the total and non-bulbar groups. Bourke et al. 
also showed a strong relationship between QoL and NIV com-
pliance, even over the long term.13
One limitation of our study is that patients during diagnostic 
PSG are exposed for the first time to PSG measurement, and 
that this could influence sleep negatively. However, after one 
month of sleeping with NIV at home, it will still be an adapta-
tion when full PSG is carried out again, especially taking into 
account the increased functional disability. Another limitation 
is the limitation of our data to results after one month. Butz et 
al. showed that patient-reported improvements in sleep emerge 
after one month of NIV treatment and could last for up to 10 
months.11 As the goal of NIV is improving sleep and QoL and 
Table 5—Correlations of therapeutic compliance (use hours) 
with baseline measurements of time of transcutaneous car-
bon dioxide spent > 55 mm Hg and changes over one month 
in time of transcutaneous carbon dioxide spent > 55 mm Hg.
Use Hours
r p
PtcCO2 > 55 total night 0.68 0.0009
PtcCO2 > 55 REM 0.62 0.0084
PtcCO2 > 55 N3 0.70 0.0073
PtcCO2 > 55 N1+N2 0.70 0.0007
∆PtcCO2 > 55 REM 0.53 0.0365
∆PtcCO2 > 55 N3 0.73 0.0076
∆PtcCO2 > 55 N1+N2 0.61 0.0041
∆, change over 1 month; PtcCO2, transcutaneous carbon dioxide; REM, 
rapid eye movement sleep; N3, slow wave sleep; N1+N2, stage 1 and 2 
sleep
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simultaneously increasing survival, longitudinal studies on 
the effect of NIV on sleep and the effect of improved sleep 
quality on survival are definitely needed. We know that PSG 
is not routinely used during NIV titration in most countries. 
Probably, three nights of titration with PSG (as performed in 
this study) will not be necessary in most patients; however, the 
findings of this study underline the importance of PSG during 
NIV titration in patients with ALS.
CONCLUSIONS
This is the first prospective study showing objective im-
provement in different sleep parameters after one month of 
NIV in ALS. Increased amounts of N3 and REM sleep with a 
decreased AAI and improved gas exchange were observed, es-
pecially in patients with none or mild bulbar involvement. Fur-
thermore, patients reported better sleep and QoL. In patients 
with severe bulbar involvement, almost no improvement was 
found, and additional research is needed on when NIV should 
be started in these patients. This study suggests that meticu-
lous titration of NIV by PSG could improve sleep in patients 
with ALS.
ABBREVIATIONS
AAI, arousal-awakening index 
ABG, arterial blood gas 
ALS, amyotrophic lateral sclerosis 
EPAP, expiratory positive airway pressure 
MIP, maximal inspiratory mouth pressure 
MQoL, McGill Quality of Life questionnaire 
NIV, non-invasive ventilation 
PSG- polysomnography
PSQI, Pittsburgh Sleep Quality Index 
PVA, patient-ventilator asynchronies 
QoL, quality of life 
REM, rapid eye movement
SAQLI, Sleep Apnea Quality of Life Index 
SE, sleep efficiency
SNIP, sniff nasal inspiratory pressure 
VC, vital capacity 
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